Financial Advisors LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,577 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.
Several other institutional investors also recently bought and sold shares of the stock. Norges Bank bought a new position in Pfizer in the 4th quarter valued at $2,219,532,000. Morgan Stanley raised its position in Pfizer by 16.4% in the 4th quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock valued at $1,973,389,000 after purchasing an additional 7,540,245 shares during the last quarter. Bank of New York Mellon Corp raised its position in Pfizer by 12.1% in the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock valued at $2,383,700,000 after purchasing an additional 6,965,496 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Pfizer in the 4th quarter valued at $162,707,000. Finally, Sanders Capital LLC increased its stake in shares of Pfizer by 10.6% in the 4th quarter. Sanders Capital LLC now owns 31,947,816 shares of the biopharmaceutical company’s stock valued at $1,280,997,000 after buying an additional 3,051,838 shares during the period. Institutional investors and hedge funds own 67.36% of the company’s stock.
Several equities research analysts have recently commented on PFE shares. Royal Bank of Canada started coverage on Pfizer in a research note on Wednesday, April 7th. They issued a “sector perform” rating and a $42.00 target price for the company. SVB Leerink decreased their price objective on Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a research note on Thursday, April 1st. Berenberg Bank reaffirmed a “neutral” rating and set a $38.00 price objective on shares of Pfizer in a research note on Tuesday, March 23rd. DZ Bank reaffirmed a “buy” rating and set a $41.00 price objective on shares of Pfizer in a research note on Wednesday, February 3rd. Finally, TheStreet cut Pfizer from a “b” rating to a “c+” rating in a research note on Friday, March 5th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $38.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The business had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. Pfizer’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period last year, the firm earned $0.55 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Recommended Story: After-Hours Trading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.